The word cardiomyopathy literally means “heart muscle disease,” and it affects an estimated 1 in 500 people, making it far more common than most realize, according to the American Heart Association. Cardiomyopathy encompasses a group of diseases in which the heart muscle becomes structurally and functionally abnormal — thickened, stretched, stiffened, or replaced by scar tissue — impairing its ability to pump blood effectively. Some forms progress silently for years before symptoms appear, while others present suddenly with life-threatening arrhythmias. Understanding the different types and their management is essential for anyone living with or at risk for this condition. For an overview of related conditions, visit our medical conditions guide.
What Happens in Cardiomyopathy
In a healthy heart, the muscular walls of the ventricles contract and relax in a coordinated rhythm, efficiently pumping blood to the lungs and body. In cardiomyopathy, the heart muscle itself is diseased. Depending on the type, the walls may become too thick, too thin, too stiff, or infiltrated with abnormal substances. The result is impaired pumping function, reduced cardiac output, and eventually heart failure.
Cardiomyopathy can also disrupt the heart’s electrical system, predisposing to dangerous arrhythmias including ventricular tachycardia and ventricular fibrillation — which can cause sudden cardiac death. In fact, cardiomyopathy is one of the leading causes of sudden cardiac arrest in young athletes and seemingly healthy adults. The CDC identifies cardiomyopathy as a major contributor to heart failure and cardiac transplantation in the United States.
Cardiomyopathies are broadly classified as primary (the heart muscle is the primary site of disease) or secondary (the heart is damaged as a consequence of a systemic condition). They are further categorized into structural types — dilated, hypertrophic, restrictive, and arrhythmogenic — each with distinct characteristics, causes, and treatment approaches.
Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is the most common form, accounting for approximately 60% of all cardiomyopathies. In DCM, the left ventricle — the heart’s main pumping chamber — becomes enlarged (dilated) and weakened, reducing its ability to contract effectively. The ejection fraction, which normally ranges from 55-70%, drops below 40% and often below 20% in severe cases.
The causes of DCM are diverse. Approximately 30-50% of cases have a genetic basis, with mutations identified in genes encoding structural proteins of the heart muscle such as titin, lamin A/C, and desmin. Acquired causes include viral myocarditis (inflammation from infections like Coxsackievirus, adenovirus, or SARS-CoV-2), chronic alcohol abuse (“alcoholic cardiomyopathy”), cocaine use, certain chemotherapy drugs (particularly anthracyclines like doxorubicin), and peripartum cardiomyopathy (occurring in the last month of pregnancy or within five months of delivery).
In many cases, no specific cause is identified, and the condition is labeled “idiopathic.” According to research published in JACC (Journal of the American College of Cardiology), genetic testing is increasingly revealing underlying mutations in patients previously thought to have idiopathic DCM, which has important implications for family screening.
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening (hypertrophy) of the heart muscle, most commonly affecting the interventricular septum. HCM is the most common genetic heart disease, affecting approximately 1 in 500 people, and is caused by mutations in genes encoding sarcomeric proteins — the contractile machinery of the heart. Over 1,500 mutations have been identified across at least 11 genes, with the most common involving beta-myosin heavy chain and myosin-binding protein C.
HCM is inherited in an autosomal dominant pattern, meaning each child of an affected parent has a 50% chance of inheriting the mutation. However, the expression is highly variable — some family members with the mutation may have severe hypertrophy and symptoms, while others may have minimal or no apparent disease.
In approximately two-thirds of HCM patients, the thickened septum obstructs blood flow out of the left ventricle during contraction — a condition known as hypertrophic obstructive cardiomyopathy (HOCM). This obstruction increases the heart’s workload and can cause symptoms including exertional chest pain, shortness of breath, dizziness, and syncope. HCM is the leading cause of sudden cardiac death in young athletes, though the absolute risk for any individual patient is relatively low. The Mayo Clinic emphasizes that risk stratification and appropriate management have made sudden death prevention highly effective.
Restrictive and Arrhythmogenic Cardiomyopathy
Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is the least common type. The ventricles become stiff and rigid, impairing their ability to relax and fill with blood between beats (diastolic dysfunction), even though contractile function may be preserved. Causes include amyloidosis (the most common identified cause, in which abnormal proteins infiltrate the heart muscle), sarcoidosis, hemochromatosis (iron overload), radiation therapy, and idiopathic fibrosis. Cardiac amyloidosis, once considered rare, is increasingly recognized — particularly transthyretin amyloidosis (ATTR), which affects an estimated 10-25% of heart failure patients with preserved ejection fraction over age 75.
Arrhythmogenic Right Ventricular Cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) involves progressive replacement of the right ventricular muscle with fibrous and fatty tissue. This disrupts normal electrical conduction and creates a substrate for dangerous ventricular arrhythmias. ARVC is usually genetic, with mutations in desmosomal proteins, and is a significant cause of sudden cardiac death in young people and athletes. Diagnosis can be challenging and typically involves a combination of cardiac MRI, ECG findings, family history, and genetic testing.
Symptoms Across All Types
The symptoms of cardiomyopathy overlap significantly across types, as they largely reflect the heart’s inability to pump blood efficiently. Shortness of breath — initially with exertion and eventually at rest — is the most common complaint. Fatigue, reduced exercise tolerance, and lower extremity swelling (edema) are hallmarks of heart failure, which is the eventual outcome of most cardiomyopathies if untreated.
Palpitations, dizziness, and syncope (fainting) may indicate arrhythmias and warrant immediate evaluation. Chest pain can occur with HCM (due to obstruction or microvascular ischemia) and occasionally with other types. In some patients, the first manifestation of cardiomyopathy is a cardiac arrest or a blood clot — the dilated, poorly contracting chambers are prone to forming thrombi that can cause stroke or peripheral embolism.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience severe shortness of breath, chest pain, fainting, or palpitations with lightheadedness. Sudden cardiac arrest from cardiomyopathy requires immediate CPR and defibrillation.
Diagnosis
Echocardiography is the first-line diagnostic tool, revealing chamber size, wall thickness, contractile function, and valve abnormalities characteristic of each cardiomyopathy type. Cardiac MRI provides more detailed tissue characterization and can detect fibrosis, fatty infiltration (in ARVC), and amyloid infiltration with late gadolinium enhancement imaging. According to the American College of Cardiology, cardiac MRI has become essential in the diagnostic workup of cardiomyopathy.
An electrocardiogram (ECG) often shows characteristic abnormalities: left bundle branch block in DCM, high voltages and repolarization changes in HCM, and low voltages in infiltrative cardiomyopathies. Holter monitoring or implantable loop recorders detect intermittent arrhythmias. Blood tests may include BNP or NT-proBNP (biomarkers of heart failure), troponin, thyroid function, iron studies, and serum protein electrophoresis (to screen for amyloidosis).
Genetic testing and counseling are increasingly important, particularly for HCM, DCM with a family history, and ARVC. Identifying a causative mutation allows cascade screening of at-risk family members. Endomyocardial biopsy — taking a small sample of heart tissue — may be necessary to confirm infiltrative diseases like amyloidosis or sarcoidosis when noninvasive testing is inconclusive.
Treatment Strategies
Treatment of cardiomyopathy depends on the specific type, severity, and underlying cause. For DCM with reduced ejection fraction, guideline-directed medical therapy (GDMT) for heart failure is the foundation. This includes ACE inhibitors or ARBs (or sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists (spironolactone or eplerenone), and SGLT2 inhibitors. These medications have been shown in numerous clinical trials to improve survival and reduce hospitalizations in heart failure with reduced ejection fraction.
For HCM, treatment focuses on symptom management and sudden death prevention. Beta-blockers and calcium channel blockers (verapamil, diltiazem) are first-line for relieving obstruction-related symptoms. Mavacamten, a cardiac myosin inhibitor approved in 2022, represents a groundbreaking advance — it directly targets the underlying mechanism of obstruction and has been shown to significantly reduce outflow tract gradients and improve symptoms. For patients with severe, refractory obstruction, septal reduction therapy (surgical myectomy or alcohol septal ablation) can provide dramatic relief.
For restrictive cardiomyopathy, treatment targets the underlying cause when possible. Tafamidis, a transthyretin stabilizer, has been shown to reduce mortality and hospitalization in ATTR cardiac amyloidosis and represents a major therapeutic advance for a previously untreatable condition. Heart failure medications are used cautiously, as patients with restrictive physiology may not tolerate aggressive diuresis or vasodilation.
Implantable cardioverter-defibrillators (ICDs) are recommended for patients at high risk of sudden cardiac death, including those with severely reduced ejection fraction (below 35%) despite GDMT, certain high-risk HCM patients, and ARVC patients with risk factors. Cardiac resynchronization therapy (CRT) may benefit DCM patients with wide QRS complex and reduced ejection fraction. For end-stage cardiomyopathy refractory to medical and device therapy, heart transplantation remains the definitive treatment, with the associated costs being a significant consideration.
Living With Cardiomyopathy
Lifestyle modifications are an important component of management. Sodium restriction (typically less than 2,000 mg daily) helps control fluid retention. Fluid restriction may be necessary for patients with severe heart failure. Moderate, regular exercise is beneficial for most cardiomyopathy patients — the old advice of strict activity restriction has largely been replaced by individualized exercise prescriptions. However, competitive athletics are generally restricted for HCM and ARVC patients due to the risk of exercise-triggered arrhythmias.
Alcohol should be strictly avoided in patients with alcohol-related DCM and limited in all cardiomyopathy patients. Cardiac rehabilitation programs provide supervised exercise, education, and psychosocial support. Weight monitoring — daily weight checks to detect early fluid retention — allows for timely medication adjustments before symptoms worsen.
Genetic counseling is essential for patients with inherited cardiomyopathies. First-degree relatives (parents, siblings, children) should be offered screening with echocardiography and, when appropriate, genetic testing. Early detection in family members can lead to preventive measures and monitoring before symptoms develop.
Frequently Asked Questions
Is cardiomyopathy the same as heart failure?
Not exactly. Cardiomyopathy refers to a disease of the heart muscle itself. Heart failure is a clinical syndrome in which the heart cannot pump enough blood to meet the body’s needs. Cardiomyopathy is one of the most common causes of heart failure, but heart failure can also result from other conditions like coronary artery disease, valve disease, and hypertension. Think of cardiomyopathy as the disease and heart failure as its most common consequence.
Can cardiomyopathy be cured?
Some forms are reversible if the underlying cause is removed. Alcohol-related DCM may improve significantly or fully resolve with abstinence. Tachycardia-mediated cardiomyopathy recovers when the arrhythmia is controlled. Peripartum cardiomyopathy resolves in about 50% of cases. Genetic and idiopathic cardiomyopathies are generally not curable but can be effectively managed with medications, devices, and, when necessary, transplantation.
Should my family members be tested if I have cardiomyopathy?
Yes, particularly for HCM, familial DCM, and ARVC, which have a strong genetic basis. First-degree relatives should undergo clinical screening with echocardiography and ECG. If a causative genetic mutation is identified, targeted genetic testing of family members can determine who is at risk and who is not. The American Heart Association recommends screening every 3-5 years for adult family members and more frequently for children and adolescents.
Can I exercise with cardiomyopathy?
For most cardiomyopathy patients, moderate exercise is recommended and beneficial. Walking, light cycling, and swimming can improve fitness, mood, and quality of life. The key exceptions are competitive or high-intensity exercise in HCM and ARVC, where vigorous activity can trigger dangerous arrhythmias. Always discuss your exercise plan with your cardiologist, who can provide an individualized recommendation based on your specific condition and risk profile.
What is the life expectancy with cardiomyopathy?
This varies enormously depending on the type, severity, cause, and response to treatment. Many patients with well-managed cardiomyopathy live full lives for decades. Survival has improved dramatically with modern therapies — five-year survival for DCM has improved from approximately 50% historically to over 80% with current guideline-directed treatment. For end-stage disease, heart transplantation offers a median survival exceeding 12 years.
Taking the Next Step
If you have been diagnosed with cardiomyopathy, partner with a cardiologist experienced in managing your specific type. Take your medications as prescribed — every day, not just when you feel unwell. Monitor your weight and symptoms daily, and contact your care team promptly if you notice changes. If your cardiomyopathy has a genetic basis, make sure your family members are aware and offered screening.
Modern cardiology has transformed cardiomyopathy from a diagnosis with limited options to one with a robust therapeutic arsenal. New medications, advanced devices, and evolving surgical techniques continue to improve outcomes. The most important thing you can do is stay engaged with your care, stay informed, and stay proactive about managing your heart health.